CASE COMMENTS: MERGERS – PHARMACEUTICAL SECTOR

Commitments: The European Commission conditionally clears the acquisition by a French pharmaceutical company of a German competitor’s Consumer Healthcare Business (Sanofi/Boehringer Ingelheim Consumer Healthtcare Business)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. By a decision of August 4, 2016, the European Commission (the "Commission") has approved, subject to commitments, the acquisition by the French pharmaceutical company Sanofi of the assets related to the Consumer Healthcare division ("Consumer Healthcare") of its German competitor Boehringer Ingelheim (the "Parties"), assets valued at €6.7 billion (the "Transaction"). This Transaction is part of a broader asset swap between the Parties as it relates to the sale by Sanofi of its Animal Health Business to Boehringer Ingelheim, valued at 11.4 billion euros, with the difference in value being offset by a payment of 4.7 billion euros to Sanofi. This second

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Clifford Chance (Paris)

Quotation

David Tayar, Commitments: The European Commission conditionally clears the acquisition by a French pharmaceutical company of a German competitor’s Consumer Healthcare Business (Sanofi/Boehringer Ingelheim Consumer Healthtcare Business), 4 August 2016, Concurrences Nº 4-2016, Art. N° 82074, pp. 132-133

Visites 123

All reviews